Medical Uses
PROCYSBI (cysteamine bitartrate) delayed-release capsules, from Horizon Therapeutics (now Amgen), are indicated for the treatment of nephropathic cystinosis in adults and children 1 year of age and older.
Cysteamine reacts with cystine trapped inside lysosomes of cystinosis patients, converting it into compounds that can exit the cell, thereby depleting the harmful cystine accumulation that damages the kidneys, eyes, and other organs. PROCYSBI’s delayed-release formulation allows twice-daily (rather than every-6-hour) dosing.
